Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 140

1.

ImmunoMembrane: a publicly available web application for digital image analysis of HER2 immunohistochemistry.

Tuominen VJ, Tolonen TT, Isola J.

Histopathology. 2012 Apr;60(5):758-67. doi: 10.1111/j.1365-2559.2011.04142.x. Epub 2012 Feb 1.

PMID:
22296215
2.

Free digital image analysis software helps to resolve equivocal scores in HER2 immunohistochemistry.

Helin HO, Tuominen VJ, Ylinen O, Helin HJ, Isola J.

Virchows Arch. 2016 Feb;468(2):191-8. doi: 10.1007/s00428-015-1868-7. Epub 2015 Oct 22.

PMID:
26493985
3.

Digital image analysis of membrane connectivity is a robust measure of HER2 immunostains.

Brügmann A, Eld M, Lelkaitis G, Nielsen S, Grunkin M, Hansen JD, Foged NT, Vyberg M.

Breast Cancer Res Treat. 2012 Feb;132(1):41-9. doi: 10.1007/s10549-011-1514-2. Epub 2011 Apr 22.

PMID:
21512768
5.
6.

Chromogenic in situ hybridisation for the assessment of HER2 status in breast cancer: an international validation ring study.

van de Vijver M, Bilous M, Hanna W, Hofmann M, Kristel P, Penault-Llorca F, Rüschoff J.

Breast Cancer Res. 2007;9(5):R68.

7.

Effects of the change in cutoff values for human epidermal growth factor receptor 2 status by immunohistochemistry and fluorescence in situ hybridization: a study comparing conventional brightfield microscopy, image analysis-assisted microscopy, and interobserver variation.

Atkinson R, Mollerup J, Laenkholm AV, Verardo M, Hawes D, Commins D, Engvad B, Correa A, Ehlers CC, Nielsen KV.

Arch Pathol Lab Med. 2011 Aug;135(8):1010-6. doi: 10.5858/2010-0462-OAR.

PMID:
21809992
8.

Impact of American Society of Clinical Oncology/College of American Pathologists guideline recommendations on HER2 interpretation in breast cancer.

Shah SS, Ketterling RP, Goetz MP, Ingle JN, Reynolds CA, Perez EA, Chen B.

Hum Pathol. 2010 Jan;41(1):103-6. doi: 10.1016/j.humpath.2009.07.001. Epub 2009 Sep 16.

PMID:
19762065
9.

Dual-colour chromogenic in-situ hybridization is a potential alternative to fluorescence in-situ hybridization in HER2 testing.

Hwang CC, Pintye M, Chang LC, Chen HY, Yeh KY, Chein HP, Lee N, Chen JR.

Histopathology. 2011 Nov;59(5):984-92. doi: 10.1111/j.1365-2559.2011.04037.x.

PMID:
22092410
10.

Image analysis of HER2 immunohistochemical staining. Reproducibility and concordance with fluorescence in situ hybridization of a laboratory-validated scoring technique.

Minot DM, Voss J, Rademacher S, Lwin T, Orsulak J, Caron B, Ketterling R, Nassar A, Chen B, Clayton A.

Am J Clin Pathol. 2012 Feb;137(2):270-6. doi: 10.1309/AJCP9MKNLHQNK2ZX.

PMID:
22261453
11.
12.

Human epidermal growth factor receptor 2 testing in gastroesophageal cancer: correlation between immunohistochemistry and fluorescence in situ hybridization.

Tafe LJ, Janjigian YY, Zaidinski M, Hedvat CV, Hameed MR, Tang LH, Hicks JB, Shah MA, Barbashina V.

Arch Pathol Lab Med. 2011 Nov;135(11):1460-5. doi: 10.5858/arpa.2010-0541-OA.

PMID:
22032573
13.

Breast cancer HER2 equivocal cases: is there an alternative to FISH testing? A pilot study using two different antibodies sequentially.

Yosepovich A, Avivi C, Bar J, Polak-Charcon S, Mardoukh C, Barshack I.

Isr Med Assoc J. 2010 Jun;12(6):353-6.

14.

Standardization of HER2 immunohistochemistry in breast cancer by automated quantitative analysis.

Gustavson MD, Bourke-Martin B, Reilly D, Cregger M, Williams C, Mayotte J, Zerkowski M, Tedeschi G, Pinard R, Christiansen J.

Arch Pathol Lab Med. 2009 Sep;133(9):1413-9. doi: 10.1043/1543-2165-133.9.1413.

PMID:
19722747
15.

Gastric HER2 Testing Study (GaTHER): an evaluation of gastric/gastroesophageal junction cancer testing accuracy in Australia.

Fox SB, Kumarasinghe MP, Armes JE, Bilous M, Cummings MC, Farshid G, Fitzpatrick N, Francis GD, McCloud PI, Raymond W, Morey A.

Am J Surg Pathol. 2012 Apr;36(4):577-82. doi: 10.1097/PAS.0b013e318244adbb.

PMID:
22314190
16.
18.

Observer prediction of HER2 amplification in HercepTest 2+ breast cancers as a potential audit instrument.

Going JJ.

Histopathology. 2011 Aug;59(2):333-5. doi: 10.1111/j.1365-2559.2011.03879.x.

PMID:
21884213
19.

Validation of the 4B5 rabbit monoclonal antibody in determining Her2/neu status in breast cancer.

van der Vegt B, de Bock GH, Bart J, Zwartjes NG, Wesseling J.

Mod Pathol. 2009 Jul;22(7):879-86. doi: 10.1038/modpathol.2009.37. Epub 2009 Mar 20.

20.

HER2-testing in 538 consecutive breast cancer cases using FISH and immunohistochemistry.

Kovács A, Stenman G.

Pathol Res Pract. 2010 Jan 15;206(1):39-42. doi: 10.1016/j.prp.2009.08.003. Epub 2009 Oct 12.

PMID:
19819642

Supplemental Content

Support Center